Showing results (71-80 of 172) with videos related to
Sort By:
Pageof 18
Rare Tumors|September 12, 2019
Extraskeletal osteosarcoma: A large series treated at a single institutionHaotong Wang, Ruoyu Miao, Alex Jacobson, et al.International Journal of Radiation Oncology, Biology, Physics|December 18, 2016
Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation TherapyPeyman Kabolizadeh, Yen-Lin Chen, Norbert Liebsch, et al.Molecular Cancer Therapeutics|September 3, 2009
A novel target for treatment of chordoma: signal transducers and activators of transcription 3Cao Yang, Joseph H Schwab, Andrew J Schoenfeld, et al.Journal of Medicinal Chemistry|March 10, 2012
Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancerZhenfeng Duan, Xin Li, Haoxi Huang, et al.Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|January 22, 2016
Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarrayYan Gao, Yunfei Liao, Jacson K Shen, et al.Scientific Reports|March 7, 2017
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.Scientific Reports|August 11, 2018
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.Oncotarget|April 1, 2015
MicroRNA-155 expression is independently predictive of outcome in chordomaEiji Osaka, Andrew D Kelly, Dimitrios Spentzos, et al.Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.Pageof 18